Neurofilament isoform alterations in the rat cerebellum following cytosine arabinoside administration
-
Add time:08/23/2019 Source:sciencedirect.com
A number of neurotoxic agents could potentially exert their action by degrading or modifying cytoskeleton components like neurofilaments (NF). Cytosine arabinoside (AraC) is an anticancer drug commonly used in leukemia treatment. Its side effects include neuronal cell death in the cerebellum and severe motor coordination deficits. We have previously shown that AraC administration (400 mg/kg bw) in adult rats reduced NF immunostaining in cerebellar neurons. To further delineate the susceptibility of individual NF isoforms (NF-H, NF-M, NF-L) to AraC, in the present study we used Western blot analysis to quantify their level. A significant and selective reduction of NF-H isoform was observed in the cerebellum of AraC-treated animals, compared to the controls. Administration of the antioxidant N-acetylcysteine (NAC) for a period of 14 days (prior to and during AraC treatment), which was previously shown to ameliorate the AraC-induced motor deficits in these animals, largely prevented the reduction in NF-H isoform. Given the significant role of NF proteins and particularly NF-H in maintaining structural integrity and synaptic transport, the observed loss of this isoform may be a key-target of AraC action in cerebellar neurons. Moreover, this study provides further data on the neuroprophylactic role of NAC in vivo against chemotherapy-induced toxicity.
We also recommend Trading Suppliers and Manufacturers of N(4)-chloroacetylcytosine arabinoside (cas 113737-52-3). Pls Click Website Link as below: cas 113737-52-3 suppliers
Prev:Two-step Enzymatic Synthesis of Guanine Arabinoside
Next:Functional Biomarker ImagingMeasurement of Tumor Hypoxia in Patients With Locally Advanced Cervical Cancer Using Positron Emission Tomography with 18F-Fluoroazomyin Arabinoside) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research paperRandomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia08/30/2019
- Recent and remote spatial memory in mice treated with cytosine arabinoside08/29/2019
- Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia08/28/2019
- Two benzophenone O-arabinosides and a chromone from Hypericum annulatum08/27/2019
- Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma08/26/2019
- Micellar electrokinetic capillary chromatography quantification of cytosine arabinoside and its metabolite, uracil arabinoside, in human serum08/25/2019
- Functional Biomarker ImagingMeasurement of Tumor Hypoxia in Patients With Locally Advanced Cervical Cancer Using Positron Emission Tomography with 18F-Fluoroazomyin Arabinoside08/24/2019
- Two-step Enzymatic Synthesis of Guanine Arabinoside08/22/2019
- ORIGINAL ARTICLEC19-Diterpenoid alkaloid arabinosides from an aqueous extract of the lateral root of Aconitum carmichaelii and their analgesic activities08/21/2019


